TARA (Protara Therapeutics, Inc.) Stock Financials & Earnings

TARAProtara Therapeutics, Inc.

Mkt Cap$228M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$53M

EPS (TTM)-$1.43

Free Cash Flow (TTM)-$49M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$40M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$12M
Q3 23	$0	$0	-$11M
Q4 23	$0	$0	-$11M
Q1 24	$0	-$83K	-$12M
Q2 24	$0	$0	-$11M
Q3 24	$0	$0	-$12M
Q4 24	$0	$0	-$14M
Q1 25	$0	$0	-$14M
Q2 25	$0	$0	-$17M
Q3 25	$0	-$88K	-$15M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$5M	$5M	—
Q1 23	$5M	$5M	—
Q2 23	$7M	$5M	—
Q3 23	$6M	$4M	—
Q4 23	$6M	$5M	—
Q1 24	$8M	$4M	—
Q2 24	$6M	$4M	—
Q3 24	$8M	$4M	—
Q4 24	$9M	$5M	—
Q1 25	$9M	$5M	—
Q2 25	$11M	$6M	—
Q3 25	$10M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$24M	$60M	$84M
Q1 23	$21M	$66M	$87M
Q2 23	$34M	$46M	$80M
Q3 23	$34M	$40M	$74M
Q4 23	$40M	$26M	$66M
Q1 24	$52M	$3M	$55M
Q2 24	$90M	$0	$90M
Q3 24	$52M	$30M	$81M
Q4 24	$163M	$7M	$170M
Q1 25	$91M	$33M	$124M
Q2 25	$31M	$91M	$122M
Q3 25	$13M	$120M	$133M

Shares Outstanding

Revenue Per Employee

Revenue / Employee